AshiBio

About AshiBio

AshiBio is a clinical-stage biotechnology company that emerged from stealth in June 2024, focusing on the development of treatments for rare bone and connective tissue disorders. The company was established in 2022 by Chief Executive Officer Pankaj Bhargava, M.D., in collaboration with the team at MPM BioImpact, a biotechnology investment firm where Dr. Bhargava also serves as an entrepreneur partner. His background includes roles as the Oncology Therapeutic Area Head at Gilead Sciences and executive positions at Sanofi and Dicerna Pharmaceuticals, where he guided development programs for oncology and rare genetic diseases.

The company's primary business involves creating a pipeline of therapeutics for conditions that currently lack adequate or approved treatment options. AshiBio's business model is centered on advancing these therapies through clinical trials to gain regulatory approval and eventual commercialization. Its funding is venture capital-backed, having secured $40 million in Seed and Series A financing. The Series A round was led by MPM BioImpact, with participation from Agent Capital, YK Bioventures, and Mirae Asset Venture Investment.

AshiBio's lead product candidate is andecaliximab, a humanized antibody that inhibits the matrix metalloproteinase-9 (MMP-9) enzyme. This antibody was licensed from Gilead Sciences and has been previously administered to approximately 1,000 patients in other clinical trials. The company's initial focus for andecaliximab is the treatment of fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder causing abnormal bone formation in muscle and soft tissues. The scientific basis for this approach was highlighted by the case of an FOP patient with a naturally occurring MMP-9 mutation who exhibited minimal disease progression. AshiBio initiated a Phase 2/3 clinical trial for andecaliximab in FOP patients and has received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency. The company is also exploring andecaliximab for non-hereditary heterotopic ossification (NHHO) and has expanded its pipeline by licensing vantictumab from Mereo BioPharma for the treatment of autosomal dominant osteopetrosis type 2 (ADO2).